Trial comparisons

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=21

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02005510-e4be815a",
        "title": "In-home HPV Screening vs Usual Care: Number of Participants That Completed Uptake of Cervical Cancer Screening",
        "summary": "2618 of 9960 against 1719 of 9891; risk difference 8.9 points, 95% interval 7.8 to 10.0; NCT02005510, Randomized Trial of In-Home Cervical Cancer Screening in Underscreened Women",
        "record": "/library/comparisons/NCT02005510-e4be815a",
        "nct_id": "NCT02005510",
        "kind": "outcome",
        "participants": 19851,
        "risk_difference": {
          "value": 0.08905704711475568,
          "lower": 0.07761992739630705,
          "upper": 0.10046695897429689
        },
        "group_1": "2,618 of 9,960",
        "group_2": "1,719 of 9,891",
        "difference": "8.9 points",
        "interval": "7.8 to 10.0",
        "trial_title": "Randomized Trial of In-Home Cervical Cancer Screening in Underscreened Women"
      },
      {
        "id": "NCT05321810-05df99e9",
        "title": "Secondary Prevention Cohort (Balanced): Apixaban vs Secondary Prevention Cohort (Balanced): Warfarin: Number of Participants With Risk of a Composite of Recurrent Stroke or SE at 18 Months: Secondary Prevention (Balanced) Cohorts",
        "summary": "1095 of 7796 against 1272 of 11601; risk difference 3.1 points, 95% interval 2.1 to 4.0; NCT05321810, Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation",
        "record": "/library/comparisons/NCT05321810-05df99e9",
        "nct_id": "NCT05321810",
        "kind": "outcome",
        "participants": 19397,
        "risk_difference": {
          "value": 0.030810924236507817,
          "lower": 0.021292051823941456,
          "upper": 0.04046147665922475
        },
        "group_1": "1,095 of 7,796",
        "group_2": "1,272 of 11,601",
        "difference": "3.1 points",
        "interval": "2.1 to 4.0",
        "trial_title": "Safety and Effectiveness of Apixaban Compared to Warfarin in Secondary Prevention in Patients With Atrial Fibrillation"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "None stated"
    }
  ],
  "next": "/api/comparisons/v1?page=22",
  "request_id": "5VBc9WFqOkc2sKWA"
}